The University of Chicago Cancer Research Center (UCCRC) Core Facility in Nuclear Magnetic Resonance (NMR) copy offers state-of-the-art instrumentation in multidimensional heteronuclear NMR spectroscopy and phase-modulation fluorescence spectroscopy for application to basic research in molecular oncology. These methods enable the structure and dynamics of cancer-related macromolecules (such as oncoproteins and growth factors) and drug interactions to be investigated in solution. The goals of the facility are: (a) to provide advice to faculty and trainees regarding the capabilities and appropriate scientific role of such methods in the context of their fields, (b) to provide """"""""hands-on"""""""" teaching and training, (c) to provide 2D, 3D and 4D homonuclear and heteronuclear NMR spectra for analysis of the structures of proteins, carbohydrates and nucleic acids in solution, (d) to provide heteronuclear relaxation times at multiple field strengths for analysis of macromolecular dynamics, (e) to provide complementary steady-state and phase-modulation fluorescence spectra of macromolecules, and (f) to provide a workstation for computer-based data analysis. The NMR spectrometers were purchased in 1995 using funds from the Division of the Biological Sciences and peer-reviewed matching funds from the National Cancer Institute. The Facility is located in the newly constructed Biological Sciences Learning Center/Jules F. Knapp Medical Research Building. Scheduling information and data output from the instruments are accessible to faculty in their offices via high-speed computer data links.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-25
Application #
6268784
Study Section
Project Start
1998-08-01
Project End
1999-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
25
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74
Lee, Ji-Hye; Park, Beom Seok; Han, Kang R et al. (2018) Insight Into the Interaction Between RNA Polymerase and VPg for Murine Norovirus Replication. Front Microbiol 9:1466
Cheng, Jason X; Chen, Li; Li, Yuan et al. (2018) RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun 9:1163
Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966

Showing the most recent 10 out of 668 publications